The ubiquitin proteasome pathway was discovered in the 1980s to be a central component
of the cellular protein-degradation machinery with essential functions in homeostasis, which …

Multiple myeloma (MM, plasma cell myeloma) is a malignant hematologic disease
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …

Inhibition of proteasome, a proteolytic complex responsible for the degradation of
ubiquitinated proteins, has emerged as a powerful strategy for treatment of multiple …

For many decades classical anti-tumor therapies included chemotherapy, radiation and
surgery; however, in the last two decades, following the identification of the genomic drivers …

Decades of research into the molecular mechanisms of cancer and the development of
novel therapeutics have yielded a number of remarkable successes. However, our ability to …

Multiple myeloma (MM) has proven clinically susceptible to modulation of pathways of
protein homeostasis. Blockade of proteasomal degradation of polyubiquitinated misfolded …

Curative responses in the treatment of multiple myeloma (MM) are limited by the emergence
of therapeutic resistance. To address this problem, we set out to identify druggable …

The number of novel therapies for the treatment of myeloma is rapidly increasing, as are the
clinical trials evaluating them in combination with other novel and established therapies …

Drug resistance remains a barrier in the clinical treatment of ovarian cancer. Proteasomal
and antioxidant activities play important roles in tumor drug resistance, and increasing …

Every day we march closer to finding the cure for multiple myeloma. The myeloma cells
inflict their damage through specialized cellular meshwork and cytokines system. Implicit in …